DDInter456 DDInter782
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Cyclophosphamide {u} (Compound) resembles {v} (Compound) Mechlorethamine
Cyclophosphamide {u} (Compound) binds {v} (Gene) CYP3A4
Cyclophosphamide {u} (Compound) downregulates {v} (Gene) ENOPH1
Cyclophosphamide {u} (Compound) causes {v} (Side Effect) Impaired healing
Cyclophosphamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Cyclophosphamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Peginterferon alfa-2a
Cyclophosphamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mitomycin
Cyclophosphamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Cyclophosphamide {u} may lead to a major life threatening interaction when taken with {v} Golimumab
Cyclophosphamide {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Cyclophosphamide (Compound) resembles Mechlorethamine (Compound)
Cyclophosphamide (Compound) binds CYP3A4 (Gene)
Cyclophosphamide (Compound) downregulates ENOPH1 (Gene)
Cyclophosphamide (Compound) causes Impaired healing (Side Effect)
Cyclophosphamide may cause a minor interaction that can limit clinical effects when taken with Modafinil
Cyclophosphamide may cause a minor interaction that can limit clinical effects when taken with Peginterferon alfa-2a
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Cyclophosphamide may lead to a major life threatening interaction when taken with Golimumab
Cyclophosphamide may lead to a major life threatening interaction when taken with Cladribine